Study on blood test for fibrosis in arthritis or sclerosis
Part of Bones, joints & muscles, Immune system & allergy, Lungs & breathing, Skin clinical trials.
This trial looks at a blood marker called FAP to see if it relates to fibrosis (tissue scarring) in people with rheumatoid arthritis or systemic sclerosis. It may help understand how the disease affects the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with rheumatoid arthritis or systemic sclerosis by a doctor.
- You are willing to provide a blood sample and answer questions.
- You do not have active cancer or a cancer history in the last 5 years.
- You do not have another major fibrotic disease (like severe liver scarring).
- You are not pregnant or breastfeeding, and have no acute infection or other autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a non-invasive light test on the skin to measure advanced sugars (AGEs) that build up in rheumatic diseases. It compares people with inflammatory rheumatic conditions to healthy volunteers to see if this test helps understand disease activity.
This study looks at a specific antibody in the blood that may help diagnose or monitor rheumatoid arthritis (RA). It aims to see if this marker can distinguish RA from other conditions.
This study follows people who are at high risk for developing rheumatoid arthritis, as well as first-degree relatives of RA patients and people with very early untreated RA. It aims to learn more about the disease so doctors can better predict and prevent it.
This trial is looking at a protein called FAP in the blood of people with fibrotic lung diseases. It aims to understand how this protein might be used as a marker to help doctors better diagnose and track these conditions.
This trial uses a special PET/CT scan with a tracer called 68Ga-FAPI-46 to see if it can better detect inflammation and scarring (fibrosis) in people with chronic diseases like scleroderma, pulmonary fibrosis, or rheumatoid arthritis. The goal is to improve diagnosis and monitoring.
This study enrolls people with confirmed fatty liver to help researchers create and validate tests that may estimate liver scarring (fibrosis). It focuses on collecting medical information and verifying the liver condition using lab/scan results, which could help improve future care.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.